378 related articles for article (PubMed ID: 16651647)
1. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
Zheng WL; Zhang GS; Xu YX; Shen JK; Dai CW; Pei MF
Leuk Res; 2008 Feb; 32(2):251-4. PubMed ID: 17920679
[TBL] [Abstract][Full Text] [Related]
4. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Roboz GJ; Ritchie EK; Curcio T; Samuel M; Provenzano J; Segovia J; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Leuk Res; 2011 Apr; 35(4):522-5. PubMed ID: 20956016
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
Musto P; Maurillo L; Spagnoli A; Gozzini A; Rivellini F; Lunghi M; Villani O; Aloe-Spiriti MA; Venditti A; Santini V;
Cancer; 2010 Mar; 116(6):1485-94. PubMed ID: 20151429
[TBL] [Abstract][Full Text] [Related]
8. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
[TBL] [Abstract][Full Text] [Related]
9. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Kantarjian H
Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
Raza A; Galili N; Smith SE; Godwin J; Boccia RV; Myint H; Mahadevan D; Mulford D; Rarick M; Brown GL; Schaar D; Faderl S; Komrokji RS; List AF; Sekeres M
Cancer; 2012 Apr; 118(8):2138-47. PubMed ID: 21887679
[TBL] [Abstract][Full Text] [Related]
11. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
[TBL] [Abstract][Full Text] [Related]
14. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
15. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
Wei W; Zhou F; Zhang Y; Guo L; Shi H; Hou J
Leuk Res; 2012 Jun; 36(6):715-9. PubMed ID: 22277680
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
Sweeney CJ; Takimoto C; Wood L; Porter JM; Tracewell WG; Darwish M; D'Andrea DM; Remick SC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):345-56. PubMed ID: 19911123
[TBL] [Abstract][Full Text] [Related]
17. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Beer TM; Tangen CM; Nichols CR; Margolin KA; Dreicer R; Stephenson WT; Quinn DI; Raghavan D; Crawford ED
Cancer; 2006 Jun; 106(12):2624-9. PubMed ID: 16688776
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with higher risk myelodysplastic syndromes.
Fukumoto JS; Greenberg PL
Crit Rev Oncol Hematol; 2005 Nov; 56(2):179-92. PubMed ID: 15979321
[TBL] [Abstract][Full Text] [Related]
20. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
